Bristol-myers Squibb Stock News

Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel; liso-cel). Bre

(RTTNews) - Antengene Corp. said that it has reached a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor, Opdivo or nivolumab. Antengene noted that the open-label Phase 1/2 trial will evaluate the investigational

ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo ® is aPD-1 checkpoint inhibitor Combination study to begin in H12022 SHANGHAI and HONG KONG , Dec. 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases, announced today a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor, Opdivo ® (nivolumab). The open-label Phase 1/2 trial will evaluate the investigational combination as a potential treatment option for patients with advanced solid tumors . "Our clinical collaboration with Bristol Myers Squibb underscores Antengene''s commitment to explore combination regimens from our portfolio with other mechanisms of action that might transform cancer care", said Jay Mei , M.D., Ph.D., Founder and CEO of Antengene. "We are excited to enter this clinical collaboration with Bristol Myers Squibb and look forward to initiating enrollment in this exciting combination regimen in the first half of 2022." ATG-017 is an oral and selective inhibitor of extracellular signalregulated protein kinase 1 and 2 (ERK1/2).

J.W. Cole Advisors Inc. increased its position in Bristol-Myers Squibb (NYSE:BMY) by 16.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 31,391 shares of the biopharmaceutical company’s stock after buying an additional 4,464 shares during the period. J.W. Cole Advisors Inc.’s holdings in Bristol-Myers Squibb were […]

Convergence Investment Partners LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 19.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,968 shares of the biopharmaceutical companys stock after purchasing an additional 953 shares during the period. Convergence []

Park Avenue Securities LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 27.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,693 shares of the biopharmaceutical companys stock after selling 6,468 shares during the quarter. Park Avenue Securities LLCs holdings []

Assenagon Asset Management S.A. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 305.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,028 shares of the biopharmaceutical companys stock after buying an additional 18,107 shares during the period. Assenagon Asset []

Global Muscular Dystrophy Treatment Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international economy. The Global Muscular Dystrophy Treatment Market Report offers vital

S. R. Schill & Associates purchased a new stake in Bristol-Myers Squibb (NYSE:BMY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,612 shares of the biopharmaceutical companys stock, valued at approximately $214,000. A number of other institutional investors have []

P.A.W. Capital Corp purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the third quarter, HoldingsChannel reports. The firm purchased 12,000 shares of the biopharmaceutical companys stock, valued at approximately $710,000. Several other institutional investors also recently modified their holdings of BMY. FMR LLC grew its holdings in Bristol-Myers Squibb by 15.0% during []

Polycythemia vera may be a rare, chronic disorder involving the production of blood cells within the bone marrow (myeloproliferation). The production of red blood cells is most ever-changing, however the assembly of white blood cells and platelets are elevated in

Ferguson Wellman Capital Management Inc. lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 73,660 shares of the biopharmaceutical companys stock after selling 185 shares during the quarter. Ferguson Wellman Capital Management Inc.s holdings []

PGGM Investments lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 16.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 493,845 shares of the biopharmaceutical companys stock after selling 94,867 shares during the quarter. PGGM Investments holdings in Bristol-Myers Squibb were worth $29,221,000 as of its most recent []

The Cell and Gene Therapy Market covers the present scenario (with the base year being 2021) and the growth prospects of global Cell and Gene Therapy market for 20212028. The report discusses the key drivers influencing market growth, opportunities, the

The advantages of advanced drug delivery systems over outmoded systems are the aptitude to deliver a drug more selectively to an exact site easier, more accurate, less frequent treating reduced erraticism in systemic drug attentions absorption that is more consistent